Cargando…
QT Assessment in Early Drug Development: The Long and the Short of It
The QT interval occupies a pivotal role in drug development as a surface biomarker of ventricular repolarization. The electrophysiologic substrate for QT prolongation coupled with reports of non-cardiac drugs producing lethal arrhythmias captured worldwide attention from government regulators eventu...
Autores principales: | Lester, Robert M., Paglialunga, Sabina, Johnson, Ian A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471571/ https://www.ncbi.nlm.nih.gov/pubmed/30884748 http://dx.doi.org/10.3390/ijms20061324 |
Ejemplares similares
-
Evaluating cardiac risk: exposure response analysis in early clinical drug development
por: Grenier, Julie, et al.
Publicado: (2018) -
Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives
por: van Haarst, Aernout, et al.
Publicado: (2019) -
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs
por: Michaud, Veronique, et al.
Publicado: (2020) -
Congenital Short QT Syndrome
por: Antzelevitch, Charles, et al.
Publicado: (2004) -
Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease
por: Paglialunga, Sabina, et al.
Publicado: (2016)